Ignite Creation Date:
2025-12-25 @ 5:02 AM
Ignite Modification Date:
2025-12-26 @ 4:03 AM
Study NCT ID:
NCT04608318
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-12-31
First Post:
2020-10-23
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
Sponsor:
German CLL Study Group
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-03-01
Start Date Type:
ACTUAL
Primary Completion Date:
2027-09
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-09
Completion Date Type:
ESTIMATED
First Submit Date:
2020-10-23
First Submit QC Date:
None
Study First Post Date:
2020-10-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-12-30
Last Update Post Date:
2024-12-31
Last Update Post Date Type:
ACTUAL